243 related articles for article (PubMed ID: 15999102)
1. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial.
Mead GM; Cullen MH; Huddart R; Harper P; Rustin GJ; Cook PA; Stenning SP; Mason M;
Br J Cancer; 2005 Jul; 93(2):178-84. PubMed ID: 15999102
[TBL] [Abstract][Full Text] [Related]
2. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
[TBL] [Abstract][Full Text] [Related]
3. Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors.
Park S; Lee S; Lee J; Park SH; Park JO; Kang WK; Park YS; Lim HY
Onkologie; 2011; 34(8-9):416-20. PubMed ID: 21934340
[TBL] [Abstract][Full Text] [Related]
4. Salvage Chemotherapy With Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin for Relapsed Germ Cell Cancer.
McKenzie HS; Mead G; Huddart R; White JD; Rustin GJS; Hennig IM; Cozens K; Cross N; Bowers M; Wheater MJ
Clin Genitourin Cancer; 2018 Dec; 16(6):458-465.e2. PubMed ID: 30115544
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel, ifosfamide and cisplatin regimen is feasible for Japanese patients with advanced germ cell cancer.
Kawai K; Miyazaki J; Tsukamoto S; Hinotsu S; Hattori K; Shimazui T; Akaza H
Jpn J Clin Oncol; 2003 Mar; 33(3):127-31. PubMed ID: 12672789
[TBL] [Abstract][Full Text] [Related]
6. [Chemotherapy-resistant germ cell cancer of the testis treated by salvage surgery: a case report].
Taue R; Harada A; Katto K; Yamamoto Y; Kishimoto T; Nakatuji Y; Tanimoto S; Oka N; Izaki H; Fukumori T; Takahashi M; Nishitani M; Kanayama HO
Hinyokika Kiyo; 2006 Apr; 52(4):293-6. PubMed ID: 16686359
[TBL] [Abstract][Full Text] [Related]
7. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer.
Motzer RJ; Sheinfeld J; Mazumdar M; Bains M; Mariani T; Bacik J; Bajorin D; Bosl GJ
J Clin Oncol; 2000 Jun; 18(12):2413-8. PubMed ID: 10856101
[TBL] [Abstract][Full Text] [Related]
9. A randomised phase 2 trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor-prognosis germ cell tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604).
Huddart RA; Gabe R; Cafferty FH; Pollock P; White JD; Shamash J; Cullen MH; Stenning SP; ;
Eur Urol; 2015 Mar; 67(3):534-43. PubMed ID: 25001888
[TBL] [Abstract][Full Text] [Related]
10. Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP).
Grimison PS; Stockler MR; Chatfield M; Thomson DB; Gebski V; Friedlander M; Boland AL; Houghton B; Gurney H; Rosenthal M; Singhal N; Kichenadasse G; Wong SS; Lewis CR; Vasey PA; Toner GC;
Ann Oncol; 2014 Jan; 25(1):143-8. PubMed ID: 24356625
[TBL] [Abstract][Full Text] [Related]
11. Current medical management of patients with poor-risk metastatic germ-cell tumors.
Albany C
Curr Opin Urol; 2018 Sep; 28(5):474-478. PubMed ID: 29979236
[TBL] [Abstract][Full Text] [Related]
12. Management of intermediate-prognosis germ-cell cancer: results of a phase I/II study of Taxol-BEP.
de Wit R; Louwerens M; de Mulder PH; Verweij J; Rodenhuis S; Schornagel J
Int J Cancer; 1999 Dec; 83(6):831-3. PubMed ID: 10597204
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors.
Feldman DR; Hu J; Dorff TB; Lim K; Patil S; Woo KM; Carousso M; Hughes A; Sheinfeld J; Bains M; Daneshmand S; Ketchens C; Bajorin DF; Bosl GJ; Quinn DI; Motzer RJ
J Clin Oncol; 2016 Jul; 34(21):2478-83. PubMed ID: 27185842
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin containing combination chemotherapy of advanced germ cell line testicular tumours.
Bodrogi I; Baki M; Horti J; Géczi L; Liszka G; Ottó S; Hindy I; Eckhardt S; Sugár J
Acta Med Hung; 1994; 50(3-4):275-92. PubMed ID: 8587840
[TBL] [Abstract][Full Text] [Related]
15. Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948).
Fosså SD; Paluchowska B; Horwich A; Kaiser G; de Mulder PH; Koriakine O; van Oosterom AT; de Prijck L; Collette L; de Wit R;
Br J Cancer; 2005 Nov; 93(11):1209-14. PubMed ID: 16251877
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel, bleomycin, etoposide, and cisplatin (T-BEP) as initial treatment in patients with poor-prognosis germ cell tumors (GCT): a phase II study.
Mardiak J; Sálek T; Sycová-Milá Z; Obertová J; Recková M; Mego M; Hlavatá Z; Brozmanová K; Risnyovzská Z; Svetlovská D; Koza I
Neoplasma; 2007; 54(3):240-5. PubMed ID: 17447857
[TBL] [Abstract][Full Text] [Related]
17. Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support.
Broun ER; Nichols CR; Turns M; Williams SD; Loehrer PJ; Roth BJ; Lazarus HM; Einhorn LH
Cancer; 1994 Mar; 73(6):1716-20. PubMed ID: 7512438
[TBL] [Abstract][Full Text] [Related]
18. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council.
de Wit R; Roberts JT; Wilkinson PM; de Mulder PH; Mead GM; Fosså SD; Cook P; de Prijck L; Stenning S; Collette L
J Clin Oncol; 2001 Mar; 19(6):1629-40. PubMed ID: 11250991
[TBL] [Abstract][Full Text] [Related]
19. Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial.
Fizazi K; Gravis G; Flechon A; Geoffrois L; Chevreau C; Laguerre B; Delva R; Eymard JC; Rolland F; Houede N; Laplanche A; Burcoveanu D; Culine S
Ann Oncol; 2014 May; 25(5):987-91. PubMed ID: 24595454
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study.
Tryakin A; Fedyanin M; Kanagavel D; Fainstein I; Sergeev J; Polockij B; Matveev V; Zakharova T; Garin A; Tjulandin S
Urology; 2011 Sep; 78(3):620-5. PubMed ID: 21764427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
